Evidence map›Paper›PMID 29937992›Full record

ArticleOncotarget2018

Neoadjuvant chemotherapy in breast cancer: a dose-dense schedule in real life and putative role of

Valentina Cocciolone, Katia Cannita, Alessandra Tessitore, Valentina Mastroiaco, Lucia Rinaldi, Stefania Paradisi, Azzurra Irelli, Paola Lanfiuti Baldi, Tina Sidoni, Enrico Ricevuto and 9 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 2 institutions in 1 country.

Valentina Cocciolone *Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.
Katia Cannita *Medical Oncology Department, S. Salvatore Hospital, University of L'Aquila, L'Aquila, Italy.
Alessandra TessitoreDepartment of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.
Valentina MastroiacoDepartment of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.
Lucia RinaldiMedical Oncology Department, S. Salvatore Hospital, University of L'Aquila, L'Aquila, Italy.
Stefania ParadisiMedical Oncology Department, S. Salvatore Hospital, University of L'Aquila, L'Aquila, Italy.
Azzurra IrelliMedical Oncology Department, S. Salvatore Hospital, University of L'Aquila, L'Aquila, Italy.
Paola Lanfiuti BaldiMedical Oncology Department, S. Salvatore Hospital, University of L'Aquila, L'Aquila, Italy.
Tina SidoniMedical Oncology Department, S. Salvatore Hospital, University of L'Aquila, L'Aquila, Italy.
Enrico RicevutoDepartment of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.
Antonella Dal MasPathology Department, S. Salvatore Hospital, L'Aquila, L'Aquila, Italy.
Giuseppe CalvisiPathology Department, S. Salvatore Hospital, L'Aquila, L'Aquila, Italy.
Gino ColettiPathology Department, S. Salvatore Hospital, L'Aquila, L'Aquila, Italy.
Antonietta CiccozziRadiology Department, S. Salvatore Hospital, L'Aquila, L'Aquila, Italy.
Laura PizzornoBreast Unit, S. Salvatore Hospital, L'Aquila, L'Aquila, Italy.
Valter RestaBreast Unit, S. Salvatore Hospital, L'Aquila, L'Aquila, Italy.
Alberto BafileBreast Unit, S. Salvatore Hospital, L'Aquila, L'Aquila, Italy.
Edoardo AlesseDepartment of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.
Corrado FicorellaDepartment of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.
University of L'Aquila · ITSan Salvatore Hospital · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDose-dense chemotherapy is one of the treatments of choice for neoadjuvant therapy in breast cancer (BC). Activating mutations in

methodsWe conducted a phase I/II study of neoadjuvant, sequential, dose-dense anthracycline/taxane chemotherapy, plus trastuzumab in HER2-positive patients and investigated the correlation of pre-treatment

resultswe established a dose-dense docetaxel recommended dose of 60 mg/m

conclusionsThis study proposes an effective and safe neoadjuvant dose-dense anthracycline/taxane schedule and suggests that

Indexed as

dose-denseneaodjuvantPIK3CAreal life

Identifiers

PMID29937992
PMCPMC6007957
OpenAlexW2805738032

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.